Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137668 · ClinicalTrials.gov registry record · Phase 1
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
A Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia, sponsored by Sacramento Pediatric Gastroenterology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02137668: Recruiting Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia, sponsored by Sacramento Pediatric Gastroenterology.
NCT02137668 is a Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia that is actively recruiting participants, run by Sacramento Pediatric Gastroenterology. The registered enrollment target is 200 participants, below the 544-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02137668, a Phase 1 study of Primary Sclerosing Cholangitis and Biliary Atresia, is actively recruiting participants, sponsored by Sacramento Pediatric Gastroenterology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Primary Outcome
Blood tests, imaging studies and/or liver biopsy changes before and while on oral vancomycin will determine the benefit of the treatment.
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
California
- Sacramento Pediatric Gastroenterology - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2010-07 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What NCT02137668 shows while recruiting
NCT02137668 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 544-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT02137668 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02137668 about?
NCT02137668 is a clinical study titled "Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin". The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions ...
What is the current status of trial NCT02137668?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2010-07. Estimated completion is 2028-07.
What conditions does trial NCT02137668 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis, Biliary Atresia.
What interventions are being tested in trial NCT02137668?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT02137668?
This trial is sponsored by Sacramento Pediatric Gastroenterology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02137668 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02137668's enrollment target sits among peer trials
200 5th of 23 higher than 19 of 23 other Primary Sclerosing Cholangitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Sclerosing Cholangitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
RECRUITING · Phase 1
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
-
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
COMPLETED · Phase 1
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia